论文部分内容阅读
目的 :探讨血清CYFRA21 -1和CA19 -9的检测对诊断胃肠道恶性肿瘤的临床价值。方法 :采用免疫放射度量分析法(IRMA)法测定74例胃肠道恶性肿瘤患者和35例健康对照者的血清CYFRA21 -1和CA19 -9含量。结果 :胃肠道恶性肿瘤组患者血清CYFRA21 -1水平(5.55±5.96ng/ml)和CA19 -9水平(73.01±86.12u/ml)明显高于健康对照组 ,差异性十分显著(P<0.001) ;在74例胃肠道恶性肿瘤中 ,血清CYFRA21 -1的阳性率为45.9 % ,血清CA19 -9的阳性率为40.5 %。联合检测两者的阳性率为66.2 %。结论 :血清CYFRA21 -1和CA19 -9对胃肠道恶性肿瘤的诊断具有较高的临床实用价值 ,联合检测两者可提高检出率
Objective: To investigate the clinical value of detecting serum CYFRA21 -1 and CA19 -9 in the diagnosis of gastrointestinal cancer. Methods: The serum levels of CYFRA21 -1 and CA19 -9 in 74 patients with gastrointestinal cancer and 35 healthy controls were determined by the method of immunoradioassay (IRMA). Results: The serum levels of CYFRA21-1 (5.55 ± 5.96ng / ml) and CA19-9 (73.01 ± 86.12u / ml) in patients with gastrointestinal cancer were significantly higher than those in healthy controls (P <0.001 ). In 74 cases of gastrointestinal malignancies, the positive rate of serum CYFRA21-1 was 45.9% and the positive rate of serum CA19-9 was 40.5%. Joint detection of the positive rate of both 66.2%. Conclusion: Serum CYFRA21-1 and CA19-9 have high clinical value in the diagnosis of gastrointestinal malignancies. Combined detection of both could increase the detection rate